Primary Biliary Cholangitis Clinical Trials

A listing of Primary Biliary Cholangitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

  • 7 views
  • 25 Oct, 2022
  • 8 locations
Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

To assess the efficacy of mindfulness-based intervention (MBI) intervention in the treatment of moderate or severe fatigue in patients with primary biliary cholangitis (PBC).

cirrhosis
cholangitis
fatigue
ursodiol
  • 1 views
  • 07 Oct, 2022
  • 1 location
  • 0 views
  • 07 Oct, 2022
  • 24 locations
Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis

. Conventional therapy with obecholic acid will improve liver function of patients with (primary biliary cholangitis)PBC. The main objectives of the study were to assess the effects of Obeticholic Acid

  • 0 views
  • 04 Oct, 2022
  • 1 location
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.

  • 0 views
  • 04 Oct, 2022
  • 55 locations
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (VANTAGE)

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis

cholangitis
bile acid
  • 0 views
  • 04 Oct, 2022
  • 25 locations
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid

Study to determine the effect of the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF) in patients with Primary Biliary

cholangitis
obeticholic acid
bezafibrate
  • 0 views
  • 28 Oct, 2022
  • 52 locations
ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

cirrhosis
cholangitis
  • 82 views
  • 24 Oct, 2022
  • 84 locations
TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib With a 52-week Extension Phase in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness (TRANSFORM)

The primary objective of this study is to evaluate the effect of setanaxib on biochemical response at Week 52 in participants with primary biliary cholangitis (PBC) and with elevated liver

  • 1 views
  • 25 Oct, 2022
  • 67 locations
Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid

Ursodeoxycholic acid (UDCA) has been the only treatment for PBC approved by US and European drug administrations. Long-term use of UDCA(13-15 mg/kg/day) in patients with PBC improves serum liver

immune globulin
fenofibrate
bile acid
cholestasis
antimitochondrial antibody
  • 0 views
  • 25 Oct, 2022
  • 1 location